PC-melanoma and YA-melanoma cells were treated with either a pharmacological inhibitor of AKT (LY294002) or a pMTORC2 inhibitor (JR-AB2-011); which confirmed inhibition of PI3K (AKT and pMTORC2) significantly reduced proliferation, OXPHOS, and ROS in YA-melanoma and PC-melanoma cells (Figures S5H–S5P). The gene discussed is AKT1; the disease is melanoma.